Heredodegenerative Disorders, Nervous System: Clinical Trials

37 trials for Heredodegenerative Disorders, Nervous System, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

37 completed. 37 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 437Completed 37

Follow Heredodegenerative Disorders, Nervous System: new trials by email Literature Review of Heredodegenerative Disorders, Nervous System trials Research Report on Heredodegenerative Disorders, Nervous System

Trials (filtered) newest first · largest first

All 37 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Dapagliflozin Administration on the Apoptosis Levels of Patients With Acute Myocardial Infarction
Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia - Acute Myocardial Infarction (AMI), STEMI - ST Elevation Myocardial Infarction (MI)
Phase 4CompletedYoga Yudhistira402024-09-212025-02-27
D-Cycloserine for Serine Palmitoyltransferase Inhibition
D-cycloserine - Hereditary Spastic Paraplegia
Phase 4CompletedMassachusetts General Hospital12024-07-102026-04-21
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
Deutetrabenazine - Huntington's Disease, Chorea
Phase 4CompletedTeva Branded Pharmaceutical Products R&D LLC502024-02-022026-08-27
N-of-1 for Beta-Blockers in Cardiac Amyloidosis
Beta blocker - Cardiac Amyloidosis, Heart Diseases
Phase 4CompletedWeill Medical College of Cornell University142024-01-312026-07-29
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
Cannabidiol Oral Solution [Epidiolex] - Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
Phase 4CompletedJazz Pharmaceuticals792023-06-292026-04-27
A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
Everolimus - Renal Angiomyolipoma
Phase 4CompletedNovartis Pharmaceuticals42023-05-012026-10-29
A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India
Elaprase - Hunter Syndrome
Phase 4CompletedTakeda52022-04-212025-01-23
Metformin in Children With Fragile X Syndrome
Metformin, Placebo - Fragile X Syndrome, Metformin
Phase 4CompletedChildren's Hospital of Fudan University372021-12-292026-08-25
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)
OAV101 - Muscular Atrophy, Spinal
Phase 4CompletedNovartis Pharmaceuticals162021-11-042024-10-09
Evaluation of the Effects of Calcitriol's in the Neurological Symptoms of Friedreich's Ataxia Patients
Calcitriol, Blood analysis for frataxin's level measurement, Blood analysis for hypercalcemia's control - Friedreich Ataxia
Phase 4CompletedBerta Alemany202021-08-252023-10-23
The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients
tafamidis meglumine - Transthyretin Amyloid Polyneuropathy (ATTR-PN)
Phase 4CompletedPfizer152021-04-282024-03-12
C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration
C-Trelin OD Tab(5mg Taltirelin Hydrate), Placebo - Spinocerebellar Degeneration
Phase 4CompletedHLB Pharmaceutical Co., Ltd.1602019-03-042023-07-24
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Everolimus - Renal Angiomyolipoma
Phase 4CompletedNovartis Pharmaceuticals402018-11-092021-09-09
Dexmedetomidine and Propofol for Pediatric MRI Sedation
propofol, Dexmedetomidine, Glycopyrrolate - Headache, Tumor
Phase 4CompletedMedical College of Wisconsin402018-03-042020-02-21
Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia
Olanzapine, Lurasidone - Schizophrenia
Phase 4CompletedAll India Institute of Medical Sciences, Bhubaneswar1002017-08-252020-03-31
Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
Ondansetron, Placebo - Obsessive-Compulsive Disorder, Tic Disorders
Phase 4CompletedNYU Langone Health1102017-06-162024-05-03
Study to Assess the Efficacy and Safety of Raxone in LHON Patients
Idebenone - Leber's Hereditary Optic Neuropathy (LHON)
Phase 4CompletedSanthera Pharmaceuticals1992016-05-012023-04-21
Effects of Intranasal Nerve Growth Factor for Acute Ischemic Stroke
Nerve Growth Factors, normal saline - Acute Ischemic Stroke
Phase 4CompletedJinling Hospital, China1062016-01-012021-08-31
Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome
Lovastatin, Placebo - Fragile X Syndrome, Genetic Diseases
Phase 4CompletedUniversity of California, Davis302016-01-012019-09-11
Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age
Elaprase for intravenous (IV) infusion - Hunter Syndrome
Phase 4CompletedShire212015-10-282026-04-02

Showing 20 of 37. Sign in to see all of them.

Narrower conditions

Tourette Syndrome (6)  ·  Tuberous Sclerosis (4)  ·  Amyloid Neuropathies, Familial (3)  ·  Fragile X Syndrome (3)  ·  Hereditary Sensory and Autonomic Neuropathies (3)  ·  Huntington Disease (3)  ·  Mucopolysaccharidosis II (3)  ·  Tic Disorders (3)  ·  Tics (3)  ·  Angiomyolipoma (2)  ·  Bulbo-Spinal Atrophy, X-Linked (2)  ·  Friedreich Ataxia (2)  ·  Lymphangioleiomyomatosis (2)  ·  Obsessive-Compulsive Disorder (2)  ·  Abdominal Neoplasms (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (37)  ·  Nervous System Diseases (37)  ·  Genetic Diseases, Inborn (36)  ·  Neurodegenerative Diseases (31)  ·  Central Nervous System Diseases (19)  ·  Brain Diseases (16)  ·  Neurologic Manifestations (15)  ·  Pathological Conditions, Signs and Symptoms (13)  ·  Congenital Abnormalities (11)  ·  Mental Disorders (11)  ·  Metabolic Diseases (11)  ·  Nutritional and Metabolic Diseases (11)  ·  Basal Ganglia Diseases (10)  ·  Movement Disorders (10)

Interventions

Everolimus (3)  ·  idursulfase (3)  ·  Riluzole (2)  ·  Adrenergic beta-Antagonists (1)  ·  Aripiprazole (1)  ·  Bupropion (1)  ·  Calcitriol (1)  ·  Cannabidiol (1)  ·  Citalopram (1)  ·  Clonidine (1)  ·  Cycloserine (1)  ·  Cysteamine (1)  ·  Dexmedetomidine (1)  ·  Doxycycline (1)  ·  Fluoxetine (1)

Sponsors

Novartis Pharmaceuticals (3)  ·  NYU Langone Health (2)  ·  Shire (2)  ·  All India Institute of Medical Sciences, Bhubaneswar (1)  ·  Berta Alemany (1)  ·  Brigham and Women's Hospital (1)  ·  Children's Hospital of Fudan University (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  HLB Pharmaceutical Co., Ltd. (1)  ·  Harvey S. Singer (1)  ·  Hospices Civils de Lyon (1)  ·  Indiana University (1)  ·  Jazz Pharmaceuticals (1)  ·  Jinling Hospital, China (1)  ·  Jody Corey-Bloom, MD, PhD (1)

Countries

United States (20)  ·  China (5)  ·  Poland (3)  ·  United Kingdom (3)  ·  Brazil (2)  ·  Germany (2)  ·  India (2)  ·  Spain (2)  ·  Taiwan (2)  ·  Thailand (2)  ·  Argentina (1)  ·  Austria (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Canada (1)

Top investigators

Harvey S Singer, MD (2)  ·  Ahmad Yasa MD (1)  ·  Anil B Mukherjee, M.D. (1)  ·  Barbara J Coffey, M.D, M.S. (1)  ·  Barbara J Coffey, MD, MS (1)  ·  Berta Alemany Perna (1)  ·  Craig A. Erickson, MD (1)  ·  Debasish Hota, MD, DM (1)  ·  Emily Stern, PhD (1)  ·  George J. Brewer (1)  ·  Lawrence D Scahill, MSN, PhD (1)

Results publications

PMID 11383973, PMID 16829550, PMID 17006758, PMID 17159456, PMID 17459549, PMID 18791076, PMID 20218790, PMID 20568658, PMID 20579510, PMID 21059347, PMID 21357874, PMID 21639796, PMID 24595507, PMID 24841414, PMID 24997880, PMID 25205361, PMID 25681004, PMID 25902842, PMID 30782512, PMID 32316911, PMID 32740676, PMID 33305808, PMID 38428428, PMID 41291951, PMID 42435131

NIH funding

2023 (2), 2014 (1), R01MH045802 (1), R24AG064025 (1), R34MH085844 (1), T32GM007748 (1)